Products for Research Use Only

DOTA-JR11

CAT: 0804-HY-P5128-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P5128-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
DOTA-JR11 is a somatostatin receptor 2 (SSTR2) antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research[1]. DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
CAS Number
1039726-31-2
Product Name Alternative
Satoreotide tetraxetan
UNSPSC
12352209
Target
Radionuclide-Drug Conjugates (RDCs) ; Somatostatin Receptor
Type
Peptides
Related Pathways
Antibody-drug Conjugate/ADC Related; GPCR/G Protein; Neuronal Signaling
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dota-jr11.html
Purity
99.14
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
O=C(N[C@@H](C(N[C@H](C(N[C@@](C(N[C@@H](CSSC[C@H](C(N1)=O)NC([C@@H](NC(CN2CCN(CCN(CCN(CC2)CC(O)=O)CC(O)=O)CC(O)=O)=O)CC3=CC=C(C=C3)Cl)=O)C(N[C@@H](C(N)=O)CC4=CC=C(C=C4)O)=O)=O)([H])[C@H](O)C)=O)CCCCN)=O)CC5=CC=C(C=C5)NC(N)=O)[C@@H]1CC6=CC=C(C=C6)NC([C@@H]7CC(NC(N7)=O)=O)=O
Molecular Formula
C74H98ClN19O21S2
Molecular Weight
1689.27
References & Citations
[1]Krebs S, et al. Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2020 Dec;47 (13) :3047-3057.|[2]Xie Q, et al. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [18F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [68Ga]Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2021 Sep;48 (10) :3129-3140.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
Scientific Category
Peptides
Clinical Information
No Development Reported
Isoform
RDC Peptide